| Bioactivity | Claficapavir (A1752) is a specific nucleocapsid protein (NC) inhibitor with an IC50 around 1 μM. Claficapavir strongly binds the HIV-1 NC (Kd=20 nM) thereby inhibiting the chaperone properties of NC and leading to good antiviral activity against the HIV-1[1]. | ||||||||||||
| Invitro | Claficapavir binds directly to HIV-1 NC, thereby inhibiting specific chaperone functions of NC including Psi RNA dimerization and complementary trans-activation response element (cTAR) DNA destabilization, and it also disrupts the proper Gag processing[1]. | ||||||||||||
| Name | Claficapavir | ||||||||||||
| CAS | 2055732-24-4 | ||||||||||||
| Formula | C17H12ClNO4S2 | ||||||||||||
| Molar Mass | 393.86 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Kim MJ, et al. Identification and characterization of a new type of inhibitor against the human immunodeficiency virus type-1 nucleocapsid protein. Retrovirology. 2015;12:90. Published 2015 Nov 6. |
Claficapavir
CAS: 2055732-24-4 F: C17H12ClNO4S2 W: 393.86
Claficapavir (A1752) is a specific nucleocapsid protein (NC) inhibitor with an IC50 around 1 μM. Claficapavir strongly
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.